Empagliflozin for type 2 diabetes mellitus - National Horizon ...

April 2012
http://www.who.int/diabetesactiononline/diabetes/basics/en/index3.html Accessed 16 March 2012.
20 NICE Pathways. Diabetes. Blood-glucose-lowering therapy for type 2 diabetes.
http://pathways.nice.org.uk/ Accessed 16 March 2012.
21 Diabetes UK. Treatments. http://www.diabetes.org.uk/Guide-to-diabetes/Treatments/ Accessed 8 March 2012.
22 ClinicalTrials.gov. Efficacy and safety study with BI 10773 vs placebo as add-on to metformin or metformin
plus sulfonylurea over 24 weeks in patients with type 2 diabetes.
http://www.clinicaltrials.gov/ct2/show/NCT01159600?term=01159600&rank=1 Accessed 22 March 2012.
23 ClinicalTrials.gov. BI 10773 comprehensive add-on study in Japanese subjects with type 2 diabetes mellitus.
http://www.clinicaltrials.gov/ct2/show/study/NCT01368081?term=01368081&rank=1#locn Accessed 22
March 2012.
24 ClinicalTrials.gov. Efficacy and safety of BI 10773 in type 2 diabetes patients on a background of pioglitazone
alone or with metformin. http://www.clinicaltrials.gov/ct2/show/NCT01210001?term=01210001&rank=1
Accessed 22 March 2012.
25 ClinicalTrials.gov. Efficacy and safety of BI 101773 with metformin in patients with type 2 diabetes.
http://www.clinicaltrials.gov/ct2/show/NCT01167881?term=01167881&rank=1 Accessed 22 March 2012.
26 ClinicalTrials.gov. Safety and efficacy of BI 10773 and sitagliptin versus placebo over 76 weeks in patients
with type 2 diabetes. http://www.clinicaltrials.gov/ct2/show/NCT01289990?term=01289990&rank=1.
Accessed 22 March 2012.
27 ClinicalTrials.gov. Safety and efficacy of BI 10773 as add-on to insulin regimen in patients with type 2
diabetes mellitus. http://www.clinicaltrials.gov/ct2/show/NCT01306214?term=01306214&rank=1. Accessed
22 March 2012.
28 Clinicaltrials.gov. 12 week efficacy and safety study of BI 10773 in hypertensive patients with type 2 diabetes
mellitus. http://www.clinicaltrials.gov/ct2/show/study/NCT01370005?term=NCT01370005&rank=1#locn
Accessed 13 April 2012.
29 ClinicalTrials.gov. Efficacy and safety of BI 10773 in patients with type 2 diabetes and renal impairment.
http://www.clinicaltrials.gov/ct2/show/study/NCT01164501?term=NCT01164501&rank=1#locn Accessed 13
April 2012.
30 ClinicalTrials.gov. BI 10773 add-on to metformin in patients with type 2 diabetes.
http://www.clinicaltrials.gov/ct2/show/NCT00749190?term=00749190&rank=1 Accessed 22 March 2012.
31 Rosenstock J, Jelaska A, Seman L et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter-
2 (SGLT-2) inhibitor in type 2 diabetes inadequately controlled on metformin. ADA 2011; Abstract 989.
32 ClinicalTrials.gov. 12 weeks treatment with 3 different doses of BI-10773 in type 2 diabetic patients.
http://www.clinicaltrials.gov/ct2/show/NCT00789035?term=NCT00789035&rank=1 Accessed 8 March 2012.
33 Ferrannini E, Seman LJ, Seewaldt-Becker E et al. The potent and highly selective soldium-glucose cotransporter
(SGLT-2) inhibitor BI 10773 is safe and effacious monotherapy in patients with type 2 diabetes
mellitus. ESAD 2010; Abstract 877.
34 ClinicalTrials.gov. BI-10773 in type two diabetes (T2D) patients, open label extension.
http://www.clinicaltrials.gov/ct2/show/NCT00881530?term=NCT00881530&rank=1 Accessed 8 March 2012.
35 British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary.
BMJ Group and RPS Publishing. London; March 2012.
The National Institute for Health Research Horizon Scanning Centre Research Programme is
funded by the Department of Health.
The views expressed in this publication are not necessarily those of the NHS, the NIHR or the
Department of Health
The NIHR Horizon Scanning Centre,
Department of Public Health and Epidemiology
University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP, England
Tel: +44 (0)121 414 7831 Fax +44 (0)121 414 2269
www.haps.bham.ac.uk/publichealth/horizon
10